Search results for "DHE"

showing 10 items of 1975 documents

Microalbuminuria and endothelial activation in treated and untreated diabetic and non-diabetic hypertensives

2004

medicine.medical_specialtymicroalbuminuriabiologybusiness.industryRenal functionendothelial activationmedicine.diseaseEndothelial activationEndocrinologyVon Willebrand factorDiabetes mellitusInternal medicineE-selectinInternal Medicinebiology.proteinmedicineadhesion moleculesMicroalbuminuriabusinessNon diabeticAmerican Journal of Hypertension
researchProduct

Effect of post-space irrigation with acid solutions on bond strength and dentin penetrability using a self-adhesive cementation system

2021

Made available in DSpace on 2022-04-29T08:29:40Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-06-01 Background: The aim of this study was to evaluate the effects of surface treatments with 1% peracetic acid (PA), solution containing 17% EDTA (SmearClear, Kerr Endodontics), solution containing a combination of 17% EDTA with 2% chlorhexidine (QMix, Dentsply Sirona) on the post-space root dentin compared to 2.5% sodium hypochlorite (NaOCl) on bond strength and resin tags length in dentin. Material and Methods: Forty human-canine roots were endodontically treated and the post space was prepared. The specimens were randomised into four groups (n = 10): control - irrigation with 2.5% NaO…

medicine.medical_specialtyself-adhesive resin cementroot dentinDentistryOperative Dentistry and Endodonticschemistry.chemical_compoundstomatognathic systemPeracetic acidFiber postmedicineDentinGeneral DentistryUNESCO:CIENCIAS MÉDICASbusiness.industryBond strengthResearchChlorhexidineCementation (geology)Endodonticsmedicine.anatomical_structurechemistrySodium hypochloriteirrigating solutionsAdhesivebusinessadhesive cementationmedicine.drugJournal of Clinical and Experimental Dentistry
researchProduct

Lovastatin stimulates p75 TNF receptor (TNFR2) expression in primary human endothelial cells

2005

HMG-CoA reductase inhibitors (statins) exert pleiotropic physiological effects. Among others they attenuate cellular responses to genotoxic and inflammatory stress. We investigated the effect of lovastatin on the expression level of TNF receptors (TNFR) in primary human endothelial cells (HUVEC). ELISA, FACS and immunocytochemical analyses show that lovastatin selectively increases the cell surface expression of TNFR2 without affecting the expression level of TNFR1. This effect of lovastatin is independent from inhibition of cell-cycle progression since cells both in G1- and G2-phase showed elevated levels of TNFR2 after lovastatin treatment. To analyze the physiological relevance of lovast…

medicine.medical_treatmentCellBiologyDownregulation and upregulationE-selectinpolycyclic compoundsGeneticsmedicineHumansReceptors Tumor Necrosis Factor Type IILovastatinReceptorCells CulturedCell adhesion moleculeCell CycleEndothelial Cellsnutritional and metabolic diseasesGeneral MedicineFlow CytometryUp-RegulationCell biologymedicine.anatomical_structureCytokineReceptors Tumor Necrosis Factor Type ICancer researchbiology.proteinlipids (amino acids peptides and proteins)Tumor necrosis factor alphaLovastatinE-Selectinmedicine.drugInternational Journal of Molecular Medicine
researchProduct

Influence of extracellular matrix proteins on the development of cultured human dendritic cells.

1998

The development of dendritic cells (DC) is still only partly understood. Recently established culture systems using CD34+ cells or monocytes as precursor cells for the generation of DC indicate the necessity of pro-inflammatory cytokines for their development. In vivo the contact to other cells or to the proteins of the extracellular matrix might also be essential for their development. In our experiments we used granulocyte-macrophage colony-stimulating factor- and IL-4-treated human monocytes as precursor cells to investigate the interaction of DC at different maturation stages with the matrix proteins fibronectin, collagen type I and collagen type IV. We demonstrate a strong beta1-integr…

medicine.medical_treatmentCellular differentiationImmunologyCD34Cell CommunicationMatrix (biology)BiologyMonocytesExtracellular matrixPrecursor cellmedicineCell AdhesionImmunology and AllergyHumansCells CulturedExtracellular Matrix ProteinsTumor Necrosis Factor-alphaIntegrin beta1Cell DifferentiationDendritic cellDendritic CellsCell biologyFibronectinsUp-RegulationFibronectinCytokineAntigens Surfacebiology.proteinCollagenLymphocyte Culture Test MixedEuropean journal of immunology
researchProduct

Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts

1995

OBJECTIVES--To investigate the influence of the Th1 and Th2 lymphokines interleukins (IL)-4 and IL-13, interferon gamma (IFN gamma), and several monokines on the adhesion of mononuclear cells to synovial fibroblasts and intercellular adhesion molecule-1 (ICAM-1) expression and cytokine production of synovial fibroblasts in patients with osteoarthritis. METHODS--Synovial fibroblasts were isolated from patients with osteoarthritis and stimulated with IL-1 beta, IL-4, IL-6, IL-10, IL-12, IL-13, tumour necrosis factor alpha (TNF alpha), and IFN gamma. Subsequently, we determined the production of IL-1 alpha, IL-1 beta, IL-6, IL-10, IL-12, IFN alpha and TNF alpha, and the expression of ICAM-1 ly…

medicine.medical_treatmentImmunologyIntercellular Adhesion Molecule-1BiologyGeneral Biochemistry Genetics and Molecular BiologyTh2 CellsRheumatologyOsteoarthritisCell AdhesionmedicineHumansImmunology and AllergyInterferon gammaCell adhesionCells CulturedInterleukin-13Interleukin-6Cell adhesion moleculeSynovial MembraneLymphokineReceptors InterleukinFibroblastsTh1 CellsIntercellular Adhesion Molecule-1Molecular biologyRecombinant ProteinsReceptors Interleukin-4Cytokinemedicine.anatomical_structureImmunologyCytokinesTumor necrosis factor alphaInterleukin-4Synovial membraneResearch Articlemedicine.drug
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Estudio de la acción proinflamatoria de Angiotensina II y su posible modulación. Papel de Angiotensina II en disfunciones endoteliales.

2002

La acumulación leucocitaria es una característica de los primeros estadios de la lesión aterosclerótica, de infarto agudo de miocardio y de enfermedades renales de diversa etiología. Receptores para Angiotensina-II (Ang-II) han sido hallados en monocitos y Ang-II puede promover la activación y adhesión de estas células. Este proceso podría desencadenar o perpetuar el daño endotelial asociado a aterosclerosis e hipertensión. Los resultados de nuestro estudio demuestran que Ang-II, a dosis subvasoconstrictoras y fisiológicas, presenta propiedades proinflamatorias in vivo a nivel agudo; en concreto, produce acumulación leucocitaria en vénulas de la microcirculación mesentérica de la rata a tra…

microscopía intravital615aterosclerosiscardiovascular systemmoléculas de adhesióndisfunción endotelialinteracciones leucocito-endotelioAngiotensina IIFarmaciahormones hormone substitutes and hormone antagonists
researchProduct

Enhanced pulmonary delivery of Salmeterol Xinafoate (SX) by mucoadhesive microparticles

2016

mucoadhesion microparticles oxidative stress
researchProduct

The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: Implications in rheumatoid…

2009

Objective. Complement activation products contribute to a large number of inflammatory diseases, including RA. We have investigated whether osteoprotegerin (OPG) may concur with the soluble terminal complement complex (SC5b-9) to the inflammatory cascade characterizing RA. Methods. Levels of SC5b-9 and OPG in the plasma and SF of patients with active RA were determined by ELISA. The presence of SC5b-9 and OPG in RA synovial lesions was analysed by immunohistochemistry. Cultured endothelial cells were used for in vitro leucocyte/endothelial cell adhesion assays. In addition, endothelial cells were exposed to SC5b-9 in order to evaluate the effects on the production of OPG protein, as well as…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyComplement systemEndotheliumNeutrophilsArthritisInflammationComplement Membrane Attack ComplexArthritis RheumatoidEndothelium; Osteoprotegerin; Inflammation; Complement systemRheumatologyOsteoprotegerinInternal medicineCell AdhesionMedicineHumansPharmacology (medical)EndotheliumCells CulturedAgedInflammationEndothelial CellDose-Response Relationship Drugbusiness.industryNeutrophilSynovial MembraneOsteoprotegerinEndothelial CellsMiddle Agedmedicine.diseaseIn vitroComplement systemUp-RegulationEndothelial stem cellEndocrinologymedicine.anatomical_structureNeutrophil InfiltrationFemaleComplement system; Endothelium; Inflammation; Osteoprotegerin; Adult; Aged; Arthritis Rheumatoid; Cell Adhesion; Cells Cultured; Complement Membrane Attack Complex; Dose-Response Relationship Drug; Endothelial Cells; Endothelium Vascular; Female; Humans; Male; Middle Aged; Neutrophil Infiltration; Neutrophils; Osteoprotegerin; Synovial Membrane; Up-Regulation; Rheumatology; Pharmacology (medical)Endothelium Vascularmedicine.symptombusinessComplement membrane attack complexHuman
researchProduct

Osteoprotegerin: multiple partners for multiple functions.

2013

Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation. However, there are additional ligands of OPG that confer various biological functions. OPG can promote cell survival, cell proliferation and facilitates migration by binding TNF-related apoptosis inducing ligand (TRAIL), glycosaminoglycans or proteoglycans. A large number of in vitro, pre-clinical and clinical studies provide evidences of OPG involvement in vascular, bone, immune and tumor biology. This review describes an overview of the different OPG ligands regu…

musculoskeletal diseasesCell SurvivalEndocrinology Diabetes and MetabolismImmunologyOsteoclastsGeneral Biochemistry Genetics and Molecular BiologyTNF-Related Apoptosis-Inducing LigandOsteoprotegerinImmunology and AllergyAnimalsHumansCell adhesionReceptorCell ProliferationbiologyActivator (genetics)Cell growthChemistryRANK LigandOsteoprotegerinCell DifferentiationIn vitroCell biologyBiochemistryRANKLbiology.proteinDecoyCytokinegrowth factor reviews
researchProduct